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REVIEW CURRENTOPINION Role of the CARMA1/BCL10/MALT1 complex
in lymphoid malignancieswww.co-hematology.com´Melanie Juilland and Margot ThomePurpose of review
The CARMA1/BCL10/MALT1 (CBM) complex is a multimeric signaling complex controlling several
important aspects of lymphocyte activation. Gain-of-function mutations in the genes encoding CBM proteins
or their upstream regulators are associated with lymphoid malignancies, whereas loss-of-function mutations
lead to immunodeficiency. This review reports on recent findings advancing our understanding of how
CBM proteins contribute to malignant and nonmalignant hematological diseases in humans.
Recent findings
Somatic gain-of-function mutations of CARMA1 (also known as CARD11), originally described for patients
with diffuse large B-cell lymphoma, have recently been identified in patients with acute T-cell leukemia/
lymphoma or Se´zary syndrome, and in patients with a B-cell lymphoproliferative disorder known as
BENTA. Loss-of-function mutations of CARMA1 and MALT1, on the other hand, have been reported to
underlie human immunodeficiency. Lately, it has become clear that CBM-dependent signaling promotes
lymphomagenesis not only via NF-kB activation, but also via the AP-1 family of transcription factors. The
identification of new substrates of the protease MALT1 and the characterization of mice expressing
catalytically inactive MALT1 have deepened our understanding of how the CBM complex controls
lymphocyte proliferation through promoting MALT1’s protease activity.
Summary
The discovery of CARMA1 gain-of-function mutations in T-cell malignancies and BENTA patients, as well
as the association of CARMA1 and MALT1 mutations with human immunodeficiency highlight the
importance of CBM proteins in the regulation of lymphocyte functions, and suggest that the protease
activity of MALT1 might be targeted to treat specific lymphoid malignancies.
Keywords
AP-1, CARD11, immunodeficiency, lymphoma, NF-kBDepartment of Biochemistry, University of Lausanne, Epalinges,
Switzerland
Correspondence to Dr Margot Thome, Department of Biochemistry,
University of Lausanne, Chemin des Boveresses 155, CH-1066 Epa-
linges, Switzerland. Tel: +41 21 692 57 37; fax: +41 21 692 57 05;
e-mail: Margot.ThomeMiazza@unil.ch
Curr Opin Hematol 2016, 23:402–409
DOI:10.1097/MOH.0000000000000257
This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where
it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially.INTRODUCTION
The multimeric CARMA1/BCL10/MALT1 (CBM)
complex, composed of the scaffold proteinCARMA1
(also known as CARD11), the adaptor protein
BCL10, and the proteaseMALT1, plays an important
role in signal transmission after antigen receptor
stimulation [1]. Triggering of the antigen receptor
induces a protein kinase C (PKC)-dependent
phosphorylation of CARMA1, which leads to a
conformational change in CARMA1. This nucleates
the formation of a fibrillar, high molecular
weight complex containing CARMA1 together with
oligomerized BCL10 and MALT1 [2,3]. CBM
complex formation is required for the activation
of the transcription factors NF-kB and AP-1, which
regulate various aspects of lymphocyte prolifer-
ation, differentiation, and survival [4]. The CBM
complex also controls transcription-independent
aspects of lymphocyte activation, such as regulationof transcript stability, cellular adhesion, and meta-
bolic changes [4]. Genetic studies using mice
deficient in CARMA1, BCL10, or MALT1 have
revealed an essential role for these CBM proteins
in immunoreceptor-induced cellular activation, as
mice lacking these proteins are immunodeficient
[4]. Moreover, inactivating germline mutations ofVolume 23  Number 4  July 2016
KEY POINTS
 Constitutive CBM signaling is present in various B- and
T-cell lymphomas, including DLBCL, MCL, ATLL, and
Se´zary syndrome.
 CBM signaling promotes lymphomagenesis via
activation of the NF-kB and AP-1 transcriptional
pathways.
 Targeting the protease activity of MALT1 may be a
promising option in the treatment of CBM-driven
lymphomas.
Role of the CARMA1/BCL10/MALT1 complex Juilland and ThomeCARMA1 and MALT1 have recently been identified
in a small number of common immunodeficiency
patients [5]. CBM hyperactivity, on the other hand,
has emerged as a hallmark of lymphomagenesis.
Originally, chromosomal translocations of BCL10
or MALT1 had been identified in lymphoma of
the mucosa-associated lymphoid tissue (MALT
lymphoma) [1]. Subsequently, gain-of-function
mutations in CARMA1 or its upstream regulator,
the B-cell receptor (BCR)-associated CD79 chains,
have been described in diffuse large B-cell lym-
phoma (DLBCL) of the activated B-cell (ABC) sub-
type [6]. The purpose of this review is to update on
recent findings describing novel gain-of-function
mutations in CARMA1 and other CBM signaling
components in an increasing number of B- and
T-cell malignancies [7,8,9
&&
–11
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] and in patients
with a lymphoproliferation disorder known asBTK
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FIGURE 1. Constitutive CBM signaling in B- and T-cell malignan
or CD79B and CARMA1/CARD11, and self-antigen recognition,
germline mutations in CARMA1, (d) generation of a MALT1-API2
nonclassical (NF-kB2) pathway, (e, f) gain-of function mutations in
T-cell co-receptor CD28 with ICOS or CTLA-4. In all figure panels
activated B-cell; ATLL, acute T-cell leukemia/lymphoma; BENTA, B
receptor; CBM, CARMA1/BCL10/MALT1; CTLA-4, cytotoxic T ly
lymphoma; ICOS, inducible costimulator; MALT, mucosa-associate
protein kinase C; TCR, T-cell receptor.
1065-6251 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseBENTA disease [12,13
&
,14
&
]. We also highlight novel
molecular insights into aspects of lymphocyte acti-
vation that are controlled by CBM-dependent AP-1
activation [15
&&
–17
&&
] and by theMALT1-dependent
cleavage of specific cellular substrates [18–20,21
&
,
22
&
,23–26].CONSTITUTIVE CARMA1/BCL10/MALT1
SIGNALING CHARACTERIZES DIFFUSE
LARGE B-CELL LYMPHOMA AND MANTLE
CELL LYMPHOMA SUBSETS
Over the last few years, constitutive activation of
CBM signaling has been recognized as a common
feature of an increasing number of B- and T-cell
malignancies and B-cell proliferative diseases
(Fig. 1). Generally, this has been linked to gain-
of-function mutations of CARMA1 or its upstream
regulators, and/or to self-antigen-driven, constitu-
tive BCR signaling [1,6].
A pathogenic role for CBM signaling was
originally discovered in ABC DLBCL, in which this
pathway can be activated or sustained by gain-of-
functionmutations inCARMA1 [27], or its upstream
regulator, the BCR-associated CD79A/B complex
[28], and by self-antigen driven BCR stimulation
[29] (Fig. 1a). Mutations in CARMA1, which were
present in 9.6% of the cases, were exclusively
located in proximity of or within the coiled-coil
region of CARMA1, which is required for the
induction of an active conformation and oligome-
rization of this protein [27] (Fig. 2a). FunctionalP
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FIGURE 2. Described CARMA1/CARD11 mutations (a) Mutations found in ABC DLBCL and BENTA. An asterisk indicates
mutations in DLBCL that were not clearly identified as ABC DLBCL. Amino acid numbers of some CARMA1 mutations [7] have
been adjusted to the UniProt sequence. (b) Mutations identified in ATLL and Se´zary syndrome; 8% of ATLL cases have a
CARMA1 deletion within the linker domain. Mutations that were not functionally tested are indicated in italics. Mutations
common to DLBCL and BENTA (a) or common to Se´zary syndrome and ATLL (b) are highlighted in blue. ABC, activated B-cell;
ATLL, acute T-cell leukemia/lymphoma; BENTA, B-cell expansion with NF-kB and T-cell anergy; CARD, caspase recruitment
domain; CC, coiled coil; DLBCL, diffuse large B-cell lymphoma; GUK, guanylate kinase domain; MAGUK, membrane-
associated guanylate kinase; PDZ, domain found in the proteins PSD95, Dlg1 and ZO-1; SH3, Src homology-3 domain.
Lymphoid biology and diseasescharacterization of these point mutants identified
for the first time CARMA1 as a ‘bona fide’ oncogene
[27]. CARMA1mutations were independently ident-
ified in DLBCLs in several other studies [8,30–33].
Most of these mutations resided in the CARD-CC
hot spot region, and are thus likely gain-of-function
mutations.
Other recurrent alterations found in ABC
DLBCL are mutations in the BCR-associated
CD79A/B chains [28]. In contrast to the CARMA1
mutations, CD79 mutations are not sufficient
to activate NF-kB signaling, but increase the surface
expression of the BCR [28]. A recent study proposes
that self-antigen stimulation is required in addition
to CD79mutations to sustain CBM signaling in ABC
DLBCL [29]. Self-antigens may also drive the growth
of other ABC DLBCL patients without detectable
CD79 mutations [34] (Fig. 1a).404 www.co-hematology.comIn addition to ABC DLBCL lymphomas, a subset
of mantle cell lymphomas (MCL) has recently been
shown to depend on chronic BCR-dependent signal-
ing, and to present constitutive MALT1 and NF-kB
activation [35]. Genome sequencing revealed no
mutations in the BCR pathway that could explain
why this subset is BCR addicted [35]. It is possible
that these MCL cases are driven by yet unknown
gene mutations and/or by nongenetic mechanisms
such as self-antigen recognition, since the repertoire
of the immunoglobulin heavy variable genes of
MCL is biased [36] (Fig. 1b).CONSTITUTIVE CARMA1 ACTIVATION
CAN CAUSE BENTA SYNDROME
Recently, germline gain-of-function mutations in
CARMA1 were identified in patients with a B-cellVolume 23  Number 4  July 2016
Role of the CARMA1/BCL10/MALT1 complex Juilland and Thomeproliferative syndrome known as B-cell expansion
with NF-kB and T-cell anergy (BENTA) [12,13
&
,14
&
]
(Fig. 1c). The resulting point mutations were local-
ized either between the CARD and the coiled-coil
domain or in the CARDmotif of CARMA1. As for the
mutants described in ABC DLBCL, this induced
enhanced NF-kB responses and CARMA1 oligome-
rization without the need for PKC-mediated
CARMA1 phosphorylation [7,12,13
&
,14
&
] (Fig. 2a).
Interestingly, the B-cell expansion phenotype of
BENTA patients is associated with an increased risk
to develop lymphoma, suggesting that CARMA1
mutations are predisposing but not by themselves
sufficient for lymphoma development.MALT LYMPHOMAS ARE DRIVEN BY
BCL10 AND MALT1 TRANSLOCATIONS
Alterations in BCR signaling downstream of
CARMA1 are a prominent feature of MALT
lymphoma. Early stages of MALT lymphomas are
driven by chronic infection with Helicobacter pylori,
while advanced stages, which do not respond to
H. pylori eradication, typically have characteristic
gene translocations that lead to BCL10 or MALT1
overexpression, or to the expression of a constitu-
tively active API2-MALT1 fusion protein [1]. Inter-
estingly, transgenic overexpression of MALT1 or
BCL10 alone in mice promotes lymphomagenesis
[37,38], and MALT1 amplification together with
p53 deletion can transform MALT lymphoma into
DLBCL [37], showing a molecular link between the
two subtypes of lymphomas. The API2-MALT1
fusion protein is constitutively active without the
need for BCR triggering, and activates not only
the canonical (NF-kB1) pathway but also the non-
canonical or alternative (NF-kB2) pathway (Fig. 1d).CONSTITUTIVE CARMA1/BCL10/MALT1
SIGNALING IS PRESENT IN SUBSETS OF
ATLL AND SE´ZARY SYNDROME
The role of CBM signaling in lymphoid malignan-
cies has been recently extended to T-cell malignan-
cies (Fig. 1e and f). Indeed, gain-of-function
mutations in CARMA1, or upstream T-cell receptor
(TCR)-signaling components, were identified in
adult T-cell leukemia/lymphoma (ATLL) [11
&&
] and
in a form of cutaneous T-cell lymphoma (CTCL)
named Se´zary syndrome [9
&&
,10
&&
] (Fig. 2b).
ATLL is known to be caused by human T-lym-
photropic virus type I (HTLV-1) infection [39]. Since
HTLV-1 has a long phase of latency, genomic alter-
ations were suspected for a long time to be involved
in the full transformation of HTLV-I-infected T cells
into ATLL. Indeed, such mutations were recently1065-6251 Copyright  2016 Wolters Kluwer Health, Inc. All rights resefound in components of the TCR-signaling
pathway, such as PLCg1, CARMA1, and PKCb,
and in the T-cell co-receptor CD28 (Fig. 1e). PLCg1,
which acts downstream of the TCR and upstream of
CARMA1, was the most frequently mutated protein,
and two of the identified PLCg1 point mutations
had already been characterized as gain-of-function
mutations in CTCL [40]. CARMA1 was frequently
mutated (24%) or amplified (12%) [11
&&
]. Some
of the CARMA1 mutations were situated in the
coiled-coil domain, similarly to ABC DLBCL, but
others were present in the linker domain between
the coiled-coil and PDZ domains (Fig. 2b) [11
&&
]. In
addition, whole-genome sequencing identified a
deletion in the linker region in 8% (4/48) of the
cases [11
&&
]. Since this linker region has been shown
to be auto-inhibitory [41], mutations in this region
most likely activate CARMA1 by blocking auto-
repression. An additional unexpected recurrent
mutation was found in PKCb [11
&&
], which is known
as the direct upstream regulator of CARMA1 in B
cells (Fig. 1). Interestingly, ATLL showed a high
frequency of co-mutations in PKCb and CARMA1,
and synergism between PKCb and CARMA1
mutations could be observed in 293T cells [11
&&
].
Finally, recurrent genetic alterations in ATLL
patients were in-frame fusions between the gene
encoding cytotoxic T lymphocyte associated
protein 4 (CTLA-4) or inducible costimulator (ICOS)
and CD28, which are predicted to lead to enhanced
CD28 signaling [39]. Since CD28 co-stimulation is
required for optimal TCR-induced CBM activation,
these findings suggest that co-stimulatory signals
can also boost CBM-dependent signaling events
in some ATLL (Fig. 1e).
Se´zary syndrome is a leukemic form of CTCL,
which can arise de novo or can be derived from
a chronic mycosis fungoides. Recently, two
studies using genomic approaches have revealed
mutations in CARMA1 [9
&&
,10
&&
], overexpression of
CARMA1 mRNA [10
&&
], or presence of a CARMA1
fusion to PIK3R3 [10
&&
] as recurrent features of
Se´zary patients. CARMA1 mutations were present
both in the coiled-coil region and in the linker
domain [9
&&
,10
&&
] (Fig. 2b), and those in the linker
region were identical to mutations found in ATLL
[11
&&
]. Similarly to ATLL, Se´zary syndrome patients
had mutations in PLCg1 and in-frame fusions
between CTLA-4 or ICOS and CD28, suggesting
that the development of these two T-cell malig-
nancies is promoted by similar gain-of-function
mutations [9
&&
,10
&&
].
Collectively, these findings suggest that the
CBM signaling pathway is a highly relevant onco-
genic pathway not only in B-cell lymphomas, but
also in an increasing spectrum of T-cell lymphomas.rved. www.co-hematology.com 405
Lymphoid biology and diseasesCARMA1/BCL10/MALT1-DEPENDENT
AP-1 ACTIVATION CONTRIBUTES TO
LYMPHOMAGENESIS
Most of the lymphomagenic activity of the CBM
pathway has been ascribed to its capacity to activate
the transcription factor NF-kB, which promotes cel-
lular survival and proliferation. However, in ABC
DLBCL, the CBM complex also activates transcrip-
tion factors of the AP-1 family, in particular those of
the JUN and ATF-type [15
&&
–17
&&
]. CBM-dependent
NF-kB and AP-1 activation likely regulates gene
expression in both synergistic and separate
manners. Crosstalk between the NF-kB and AP-1
pathways can be mediated by synergistic promotor
binding and activation [42]. IL-6, which promotes
ABC DLBCL proliferation, is an example of a gene
that is synergistically upregulated by both
transcription factors [43]. Support for the existence
of separate target genes, on the other hand, comes,
for example, from experiments in which either the
NF-kB or AP-1 pathways are specifically inhibited
with dominant negative IkB, or A-Fos constructs,
respectively. This impairs the viability of ABC
DLBCL cell lines with distinct (fast versus slow)
kinetics [15
&&
]. However, the full range of AP-1 target
genes controlling lymphoma cell viability remains
to be identified. A recent study has revealed an
important role for AP-1 (and in particular c-Jun
and JunB) in the control of genes required for the
interaction of DLBCL with the tumormicroenviron-
ment [17
&&
]. Indeed, the expression of such c-Jun-
regulated genes is significantly enriched in patients
with disseminated, extranodal DLBCL [17
&&
].
The regulation and composition of AP-1
complexes in CBM-driven lymphomas has recently
gained considerable attention. The JUN subfamily
member c-Jun is known to be activated and stabil-
ized by a c-Jun N-terminal kinase (JNK)-dependent
phosphorylation [44]. BCR-induced JNK activation
requires CARMA1 [45,46], and increased JNK
activity and c-Jun expression is detectable in B-cells
from mice expressing an oncogenic CARMA1
variant, which promotes aggressive B-cell lympho-
proliferation [16
&&
]. JNK activation is also promoted
by a human CARMA1 mutant that was identified
in Se´zary syndrome [9
&&
]. The exact role of JNK in
CBM-driven AP-1 activation and lymphomagenesis
remains unclear, however, since pharmacological
JNK inhibition does not systematically affect c-Jun
levels in CBM-driven ABC DLBCL cell lines [15
&&
].
Biochemical studies reveal that in these cell lines,
c-Jun preferentially forms heterodimers with AP-1
subunits of the ATF subfamily, such as ATF2, ATF3,
and ATF7 [15
&&
]. The resulting JUN/ATF complexes
are essential for the CBM-driven proliferation of
ABC DLBCL cell lines, and ATF3 expression is a406 www.co-hematology.comhallmark of human ABC DLBCL [15
&&
]. Collectively,
these studies reveal a critical role for CBM-depend-
ent activation of the AP-1 family of transcription
factors in lymphomagenesis, but the identity and
contribution of individual AP-1 target genes remain
to be further explored.
CARMA1/BCL10/MALT1-DEPENDENT
LYMPHOMAGENESIS REQUIRES THE
PROTEASE ACTIVITY OF MALT1
Over the last 8 years, our understanding of
CBM-driven lymphomagenesis has considerably
deepened with the discovery that MALT1, initially
believed to act mainly as a scaffold protein, func-
tions as an active protease cleaving multiple
substrates to promote lymphocyte proliferation
(Table 1) [18,23]. The MALT1 protease activity sus-
tains NF-kB activation by the cleavage of RelB [19],
which forms transcriptionally inactive complexes
with RelA and c-Rel, and by the cleavage of the
deubiquitinating enzyme A20 [18], which deubiqui-
tinates and thereby inactivates several regulators of
NF-kB [49]. MALT1 also undergoes auto-processing;
this contributes to NF-kB activation in a manner
that is not yet understood at the molecular level
[20].
An interesting new twist to MALT1’s enzymatic
role in NF-kB regulation comes from the recent
identification of HOIL-1 as a novel MALT1 substrate
in lymphocytes and lymphoma cells [21
&
,22
&
].
HOIL-1 is a component of the linear ubiquitin chain
assembly complex (LUBAC), which comprises
HOIL-1, HOIL-1 interacting protein (HOIP), and
Sharpin, and promotes NF-kB activation by addition
of linear (aminoterminally-linked) polyubiquitin
chains on its substrates [50]. Interestingly, rare
germline polymorphisms in the gene encoding
HOIP (also known as RNF31), which lead to an
increased HOIL-1/HOIP interaction and NF-kB
activation, are enriched in ABC DLBCL [51].
MALT1-dependent HOIL-1 cleavage reduces linear
ubiquitination of cellular proteins, and has thus
been proposed to provide negative feedback on
the NF-kB pathway [21
&
,22
&
,52].
Controlling NF-kB activation is so far the best-
studied function of the protease activity of MALT1.
However, MALT1 cleaves additional substrates that
promote other aspects of lymphocyte activation,
including AP-1 activation [via the cleavage of the
deubiquitinating enzyme cylindromatosis (CYLD)
[24]], regulation of transcript stability (via cleavage
of RNA stability regulators Regnase-1 and Roquin-
1/-2 [25,26]) and cellular adhesion (via cleavage
of BCL10 [23]). It is likely that the cleavage of
all reported MALT1 substrates contributes in one
way or another to lymphomagenesis by promotingVolume 23  Number 4  July 2016
Table 1. Overview of MALT1 and API2-MALT1 substrates and functional consequences of their cleavage
Substrate Cleavage site Consequence References
MALT1
A20 GASR439G NF-kB1 activation [18]
RelB LVSR85G NF-kB1 activation [19]
MALT1 LCCR149A NF-kB1 activation [20]
HOIL LQPR165G NF-kB1 termination [21
&,22&]
BCL10 LRSR228T Adhesion [23]
CYLD FMSR324G AP-1 activation [24]
Regnase-1 LVPR111G mRNA stabilization [25]
Roquin-1 LIPR510G/MVPR579G mRNA stabilization [26]
Roquin-2 LISR509T mRNA stabilization [26]
API2--MALT1
NIK CLSR325G NF-kB2 activation [47]
LIMA1 PDSR206A / FKSK289G Proliferation and migration [48
&]
Consensus L-X-P/S-R-G
Role of the CARMA1/BCL10/MALT1 complex Juilland and Thomecellular proliferation, survival, adhesion and
possibly migration.
A distinct and unique profile of MALT1
substrates have been identified in cells derived from
MALT lymphoma expressing the API2 (also known
as c-IAP2-MALT1 fusion protein [1] (Fig. 1d). This
fusion protein is constitutively active and cleaves
specific substrates that are recruited by the API2
moiety. One such substrate is the Ser/Thr kinase
NIK [47], which has a known role as an activator
of the noncanonical/NF-kB2 pathway. Recently, the
tumor suppressor protein LIMA1a has been ident-
ified as an additional API2-MALT1-specific substrate
[48
&
]. LIMA1a cleavage disrupts the tumor suppres-
sor function of LIMA1a, but it also results in the
release of its Lim domain, an LMO-like oncogenic
protein, to promote B-cell proliferation and
adhesion [48
&
].PROTEASE ACTIVITY OF MALT1 COULD
BE TARGETED TO TREAT LYMPHOMAS
The discovery and understanding of MALT1’s pro-
tease activity has rapidly fostered efforts to develop
MALT1 inhibitors for the therapy of lymphomas
addicted to MALT1 signaling. So far, two types
of small molecule MALT1 inhibitors have been
identified by high throughput screening: pheno-
thiazine-derivatives such as mepazine and thiorida-
zine, which act as reversible allosteric MALT1
inhibitors [53], and MI-2, an active site-directed
irreversible MALT1 inhibitor [54]. Both types of
inhibitors were shown to efficiently slow down
the growth of ABC DLBCL in xenograft models
[53,54]. Whether MALT1 inhibitors show similar1065-6251 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseactivity against other types of hematological malig-
nancies remains to be explored. Lymphoma/
leukemia types that should be considered as poten-
tial candidates for MALT1 inhibitor treatments
include MALT lymphomas and MCL, chronic
lymphocytic leukemia with stereotyped and poten-
tially auto-reactive BCRs [6], and T-cell lymphomas
with gain-of function mutations in CBM signaling,
such as ATLL [11
&&
] and Se´zary syndrome [9
&&
,10
&&
].
Therapeutic MALT1 inhibition should be particu-
larly useful in patients who develop Ibrutinib-resist-
ant mutations in BTK or who have mutations in
signaling components downstream of BTK or ITK,
such as PLCg, PKCb and CARMA1. In the future, the
identification of lymphomas with constitutive
MALT1 activitymay be facilitated byMALT1 activity
probes that are under development [55,56]. Other
future developments may include the design/dis-
covery of inhibitors that specifically target the scaf-
fold (rather than the protease) function of MALT1.
This may, alone or in combination with MALT1
protease inhibitors, open additional avenues for
the treatment of CBM-dependent lymphomas.CONCLUSION
Constitutive activation of the CBM complex, and/or
of its protease component MALT1, is now identified
in subsets of an increasing number of lymphoid
malignancies including DLBCL, MALT lymphomas,
MCL, ATLL, and Se´zary syndrome, and is also
likely to underlie disorders associated with milder
lymphoproliferation, such as BENTA. Targeting
the BCR/TCR–BTK/ITK–CBM–NF-kB pathway with
small molecule drugs therefore presents a promisingrved. www.co-hematology.com 407
Lymphoid biology and diseasestherapeutic strategy. Ongoing efforts to develop
MALT1 inhibitors should in particular benefit
patients who develop ibrutinib resistance or who
have gain-of-function mutations in signaling
components acting downstream of BTK. Further
exploration of CBM activation in a broader range
of hematological malignancies will certainly reveal
additional lymphoma/leukemia subsets with
MALT1 addiction.Note added in proof
A new report identifying HOIL-1 as a MALT1 sub-
strate has recently been published [57].
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